Said Sarmad, Nwosu Azikiwe C, Mukherjee Debabrata, Hernandez German T
Division of Nephrology & Hypertension, Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, Texas, USA 79905.
Cardiovasc Hematol Disord Drug Targets. 2014;14(1):64-70. doi: 10.2174/1871529x14666140701095849.
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4(th) approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.
二肽基肽酶-4抑制剂（DPP-4抑制剂）是有效且安全的基于肠促胰岛素的口服降糖药物。在临床前研究中，DPP-4抑制剂已在2型糖尿病患者中显示出与血糖控制无关的心血管益处。自2005年以来，多种DPP-4抑制剂（西他列汀、利格列汀和沙格列汀）已在美国临床应用。自2013年以来，阿格列汀是市场上第4种获批的DPP-4抑制剂。研究表明，在新诊断的2型糖尿病患者中，阿格列汀不劣于对照药物。阿格列汀可有效用作单药治疗或与其他降糖药物联合使用的附加药物，对血糖控制和糖化血红蛋白（HbA1C）水平有良好效果。
